Moreover, although TGF-β typically represses NF-κB signaling in normal cells, recent evidence suggests an aberrant ability of TGF-β signaling to activate NF-κB signaling in several different cancers [14,15] as a means of promoting malignant tumor cell phenotypes. The gene discussed is NFKB1; the disease is cancer.